Current News

December 11, 2017

Morphotek and Rockefeller University Form a Sponsored Research Agreement to Study the Immunosuppressive Effects of the Tumor Shed Antigen CA125 and its Potential Impact in Future Patient Therapies
Read More

December 7, 2017

Morphotek to Present its Proprietary RESPECT Antibody-Drug Conjugate (ADC) Technology at the Upcoming Antibody Engineering & Therapeutics Conference in San Diego
Read More

December 4, 2017

Morphotek Announces Initiation of Phase 1 Study of Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202 in Solid Tumors with Folate Receptor Alpha Expression
Read More

November 14, 2017

Morphotek to Present its Proprietary RESPECT Antibody Drug Conjugate (ADC) Technology at the Upcoming 9th Annual PEGS Europe in Lisbon
Read More

September 19, 2017

Morphotek to Present Preclinical Data on Antibody-Drug Conjugate MORAb-202 at the Upcoming 8th Annual World ADC in San Diego
Read More

September 6, 2017

Morphotek Announces Collaboration Agreement with the Johns Hopkins University to Research and Develop Novel Monoclonal Antibody-Based Therapies Targeting Missplicing-Associated Surface Antigens
Read More

September 5, 2017

Morphotek, Inc. Announces an Agreement with Fujirebio Diagnostics, Inc to Commercialize the CA125 II Assay as A Companion Diagnostic for Farletuzumab
Read More

July 11, 2017

Morphotek Announces Publication Uncovering One of the Mechanisms by Which the Tumor-Produced CA125 Protein Suppresses Immune-Mediated Killing Via Farletuzumab
Read More

April 26, 2017

Morphotek to Present its Proprietary RESPECT Antibody Drug Conjugate (ADC) Technology at the Upcoming 13th Annual PEGS Summit in Boston
Read More

April 3, 2017

Morphotek Launches Antibody Drug Conjugate Services Business
Read More

Displaying results 1-10 (of 136)
 |<  < 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10  >  >| 

News & Events